Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02289690 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer
A Phase 1 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 1
- Development phase
- 221
- Enrollment target
NCT02289690 is a Phase 1 study that has completed, run by AbbVie. The registered enrollment target is 221 participants.
The verdict
NCT02289690, a Phase 1 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 221 participants
- Enrollment target
Study Summary
The study seeks to assess the efficacy of veliparib (ABT-888) in combination with carboplatin and etoposide in participants with extensive disease small cell lung cancer (ED SCLC).
Interventions
- DRUG Carboplatin
- DRUG Placebo
- DRUG Etoposide
- DRUG Veliparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 221 participants |
| Start Date | 2014-10-13 |
| Est. Completion | 2019-04-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02289690
The ClinicalTrials.gov registry entry for NCT02289690 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 221 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.
NCT02289690 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02289690 about?
NCT02289690 is a clinical study titled "Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer". The study seeks to assess the efficacy of veliparib (ABT-888) in combination with carboplatin and etoposide in participants with extensive disease small cell lung cancer (ED SCLC).
What is the current status of trial NCT02289690?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 221 participants. The study started on 2014-10-13. Estimated completion is 2019-04-17.
What interventions are being tested in trial NCT02289690?
The interventions under investigation include: Carboplatin (DRUG), Placebo (DRUG), Etoposide (DRUG), Veliparib (DRUG).
Who is sponsoring clinical trial NCT02289690?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.